GANX
NASDAQGain Therapeutics Inc.
Price$1.72+0.09 (+5.85%)
01:30 PM07:45 PM
News · 26 weeks31+267%
2026-01-182026-07-12
Mix2090d
- SEC Filings8(40%)
- Insider6(30%)
- Other5(25%)
- Earnings1(5%)
Latest news
25 items- INSIDERSEC Form 4 filed by Director Goldstein Dov A Md4 - Gain Therapeutics, Inc. (0001819411) (Issuer)
- INSIDERSEC Form 4 filed by Director Nicaise Claude4 - Gain Therapeutics, Inc. (0001819411) (Issuer)
- INSIDERSEC Form 4 filed by Director Islam Khalid4 - Gain Therapeutics, Inc. (0001819411) (Issuer)
- INSIDERSEC Form 4 filed by Director Melincoff Gwen A4 - Gain Therapeutics, Inc. (0001819411) (Issuer)
- INSIDERSEC Form 4 filed by Director Riley Jeffrey Scott4 - Gain Therapeutics, Inc. (0001819411) (Issuer)
- INSIDERSEC Form 4 filed by Director Hasler Hans Peter4 - Gain Therapeutics, Inc. (0001819411) (Issuer)
- SECGain Therapeutics Inc. filed SEC Form 8-K: Other Events8-K - Gain Therapeutics, Inc. (0001819411) (Filer)
- PRGain Therapeutics CEO Gene Mack Issues Letter to Shareholders and Provides Operational UpdateBETHESDA, Md., July 16, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today provided the following letter to shareholders from the Company’s President and CEO, Gene Mack: To our valued Shareholders, As we progress through 2026 and look ahead to delivering continued significant progress, I want to thank you for your steadfast support of Gain Therapeutics. The year has been one of meaningful scientific progress as we achieved critical inflection points related to the clinical development of rexaceract, forme
- SECGain Therapeutics Inc. filed SEC Form 8-K: Other Events8-K - Gain Therapeutics, Inc. (0001819411) (Filer)
- PRGain Therapeutics Receives FDA Clearance of IND to Advance GT-02287 into Phase 2 Clinical Development for Parkinson’s DiseaseIND authorization paves the way for initiation of GT-02287 Phase 2 clinical development in the U.S., expected during 3Q26 FDA’s decision follows positive Phase 1 results for GT-02287 in both healthy volunteers and people with Parkinson’s disease demonstrating both biomarker and clinical evidence of activity with favorable safety and tolerability GT-02287 is the first allosteric modulator developed from Gain’s Magellan™ AI drug discovery platform to receive IND clearance BETHESDA, Md., June 29, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of a
- SECGain Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Gain Therapeutics, Inc. (0001819411) (Filer)
- PRGain Therapeutics to Present at H.C. Wainwright 7th Annual Neuro Perspectives Expert SummitBETHESDA, Md., June 10, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that Gene Mack, President and CEO, will participate in a virtual fireside chat and one-on-one meetings at the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit, being held in a hybrid format from June 15-16, 2026. Fireside Chat Details Date and Time: Monday, June 15, 2026; replay beginning 7:00 a.m. EDT Access a replay of the fireside chat here or visit the "Investors & Media/News & Events" section of the Compa
- SECGain Therapeutics Inc. filed SEC Form 8-K: Other Events8-K - Gain Therapeutics, Inc. (0001819411) (Filer)
- PRGain Therapeutics Presents Positive Interim Data from Phase 1b Clinical Study of GT-02287 at 3rd International GBA1 Meeting 2026MDS-UPDRS scores remained stable and durable across overall study population after 150 days of treatment with GT-02287 Differential response between participants with low and high baseline GluSph continues, with a difference of 4.8 points in the sum of MDS-UPDRS Part II and Part III scores between the two groups at Day 150 Most common benefits reported by study participants include meaningful improvements in specific functional areas such as smell and taste, sleep, and balance or gait BETHESDA, Md., May 26, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next ge
- SECSEC Form 10-Q filed by Gain Therapeutics Inc.10-Q - Gain Therapeutics, Inc. (0001819411) (Filer)
- SECGain Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Gain Therapeutics, Inc. (0001819411) (Filer)
- PRGain Therapeutics Reports Financial Results for First Quarter 2026 and Provides Corporate UpdateBETHESDA, Md., May 11, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today reported financial results for the quarter ended March 31, 2026, and provided a corporate update. "The first quarter of 2026 marked another exciting quarter for Gain, as we continued to build on the important advancements achieved in 2025 related to both the scientific understanding and clinical development of our lead candidate GT-02287, in development for the treatment of Parkinson's disease with or without a GBA1 mutation. This is
- SECSEC Form DEFA14A filed by Gain Therapeutics Inc.DEFA14A - Gain Therapeutics, Inc. (0001819411) (Filer)
- SECSEC Form DEF 14A filed by Gain Therapeutics Inc.DEF 14A - Gain Therapeutics, Inc. (0001819411) (Filer)
- PRGain Therapeutics Announces Oral Presentation at 3rd International GBA1 Meeting 2026BETHESDA, Md., April 24, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced an oral presentation at the 3rd International GBA1 Meeting 2026, being held May 22-23, 2026, in Phoenix, AZ. Details of the oral presentation are as follows:Presentation Title: "An update on the development of the GCase modulator GT-02287 for Parkinson's disease"Presenter:Jonas Hannestad, M.D., Ph.D., Chief Medical Officer of GainSession Name:In the pipeline: updates from pharma on ongoing preclinical studies and clinical
- INSIDERSEC Form 4 filed by Mack Gene4 - Gain Therapeutics, Inc. (0001819411) (Issuer)
- INSIDERSEC Form 4 filed by Fuggetta Gianluca4 - Gain Therapeutics, Inc. (0001819411) (Issuer)
- SECSEC Form 10-K filed by Gain Therapeutics Inc.10-K - Gain Therapeutics, Inc. (0001819411) (Filer)
- SECGain Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Gain Therapeutics, Inc. (0001819411) (Filer)
- PRGain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2025 and Provides Corporate UpdateBETHESDA, Md., March 26, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today reported financial results for the fourth quarter and year ended December 31, 2025, and provided a corporate update. "We are encouraged by the progress made in 2025, as we made important advancements related to both the scientific understanding and clinical development of our lead candidate GT-02287, in development for the treatment of Parkinson's disease with or without a GBA1 mutation. The promising impact GT-02287 has on the cau
GANX FAQ
7 questionsWhat does Gain Therapeutics Inc. do?
Gain Therapeutics, Inc., a development stage biotechnology company, develops various therapeutics to treat diseases caused by protein misfolding. It focuses on lysosomal storage disorders, such as rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover novel allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites and restore protein folding treating the underlying disease. It is developing structurally targeted allosteric regulator candidates to treat various diseases...Where does GANX stock trade?
Gain Therapeutics Inc. (GANX) is listed on NASDAQ.What sector and industry is GANX in?
Gain Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Gain Therapeutics Inc. go public?
Gain Therapeutics Inc. (GANX) completed its IPO in 2021.What are analysts saying about GANX?
Gain Therapeutics Inc. has had 4 recent analyst actions on file. The most recent action was from Scotiabank: Sector Outperform with a $1200.00 price target on 2025-03-07. Recent price targets range from $700.00 to $2100.00.What companies are similar to GANX?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare GANX side-by-side with any of them on Quantisnow.How can I track GANX on Quantisnow?
Quantisnow aggregates Gain Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow GANX to receive live email and push alerts on every new disclosure.